Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Here comes the anti-CRISPR protein AcrVIB1, a promising inhibitor whose precise role has not yet been determined. In cooperation with the Helmholtz Centre for Infection Research (HZI) in ...

Bacteriophages, the most abundant life form on Earth, infect bacterial cells and influence the structure of the microbial ...

Current research in the Doudna lab focuses on discovering and determining the mechanisms of novel CRISPR-Cas and associated proteins; developing genome editing tools for use in vitro, in plants, and ...

The future of medicine is being shaped by a confluence of factors at play. If there are worries galore around drug resistant ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.